9 résultats
VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial
Auteurs / Authors
Levallet G, Dubois F, Elie N, Creveuil C, Brosseau S, Danel C, Scherpereel A, Lantuejoul S, Mazières J, Greillier L, Audigier-Valette C, Bergot E, Moro-Sibilot D, Molinier O, Léna H, Monnet I, Morin F, Gounant V, Zalcman G
Journal / Conference
Lung Cancer
Année / Year
2023
PMID / session
Etude IFCT
A Defect of Amphiregulin Release Predicted Longer Survival Independently of YAP Expression in Patients with Pleural Mesothelioma in the IFCT-0701 MAPS Phase 3 Trial
Auteurs / Authors
Maille E, Levallet J, Dubois F, Antoine M, Danel C, Creveuil C, Mazieres J, Margery J, Greillier L, Gounant V, Moro-Sibilot D, Molinier O, Léna H, Monnet I, Bergot E, Langlais A, Morin F, Sherpereel A, Zalcman G, Levallet G
Journal / Conference
International Journal of Cancer
Année / Year
2022
PMID / session
Etude IFCT
Post-Discontinuation Treatments in IFCTGFPC-0701 MAPS Trial: Real-World Effectiveness of 2nd-Line (2L) Treatments for Mesothelioma
Auteurs / Authors
G. Zalcman, S. Brosseau, J. Mazieres, J. Margery, L. Greillier,
C. Audigier-Valette, D. Moro-Sibilot, O. Molinier, R. Corre,
I. Monnet, V. Gounant, F. Rivière, R. Gervais, H. Janicot, C. Locher,
A. Langlais, J-J. Parienti, F. Morin, A. Scherpereel
Journal / Conference
WCLC
Année / Year
2019
PMID / session
Etude IFCT
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort
Auteurs / Authors
Brosseau S, Danel C, Scherpereel A, Mazières J, Lantuejoul S, Margery J, Greillier L, Audigier-Valette C, Gounant V, Antoine M, Moro-Sibilot D, Rouquette I, Molinier O, Corre R, Monnet I, Langlais A, Morin F, Bergot E, Zalcman G, Levallet G
Journal / Conference
Clinical Lung Cancer
Année / Year
2019
PMID / session
Etude IFCT
MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
Auteurs / Authors
Maille E, Brosseau S, Hanoux V, Creveuil C, Danel C, Bergot E, Scherpereel A, Mazières J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Langlais A, Morin F, Levallet G, Zalcman G
Journal / Conference
British Journal of cancer
Année / Year
2019
PMID / session
Etude IFCT
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Auteurs / Authors
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A
Journal / Conference
The Lancet
Année / Year
2016
PMID / session
Etude IFCT
Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial
Auteurs / Authors
Gerard Zalcman , Julien Mazières , Jacques Margery , Laurent Greillier , Clarisse Audigier-Valette , Denis Moro-SibilotOliver Molinier , Romain Corre , Isabelle Monnet , Valérie Gounant , Henri Janicot , Radj Gervais , Chrystele Locher , Bernard Milleron , Quan Tran , Marie Paule Lebitasy , Franck Morin , Christian Creveuil , Jean-Jacques Parienti , Arnaud Scherpereel ,
Journal / Conference
ASCO
Année / Year
2015
PMID / session
Etude IFCT